BMEA — Biomea Fusion, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840439 ·
Last close
$1.29
Market Cap
$93.27M
52W High
$2.99
52W Low
$0.87
ADV30
2,402,224
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,766,000 | -8,328,000 | 36,873,000 | 34,824,000 | 24,736,000 |
| Mar 2026 | 0 | — | — | — | 46,385,000 | 44,693,000 | 27,666,000 |
| Dec 2025 | 0 | — | -11,719,000 | 4,612,000 | 58,572,000 | 55,812,000 | 29,020,000 |
| Sep 2025 | 0 | — | -18,600,000 | -16,407,000 | 55,187,000 | 46,642,000 | 39,568,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,189,000
Investing CF
$550,000
Financing CF
$25,239,000
CapEx
$-82,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-469,791,000
Inventory
—
Receivables
$22,000
ST Investments
—
EBIT TTM
$-55,859,000
Pretax Income TTM
$-32,538,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,307,000 | -61,797,000 | 58,572,000 | 29,020,000 | 29,552,000 | -70,371,000 |
| Dec 2024 | 0 | -144,070,000 | -138,426,000 | 79,938,000 | 28,365,000 | 51,573,000 | -119,894,000 |
| Dec 2023 | 0 | -126,135,000 | -117,255,000 | 199,927,000 | 30,690,000 | 169,237,000 | -96,592,000 |
| Dec 2022 | 0 | -83,634,000 | -81,828,000 | 129,307,000 | 20,768,000 | 108,539,000 | -62,417,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.94
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.50 · spot: $1.29 · call volume: 1,010 · put volume: 1,908
Expected Move to 2026-10-16:
±$0.47
(36.43%) —
implied range
$0.82 –
$1.76
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BGM | BGM Group Ltd. | $92.87M | $0.24 | — |
| PMN | ProMIS Neurosciences Inc. | $95.51M | $10.65 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $91.03M | $3.16 | — |
| RLYB | Rallybio Corp | $90.54M | $17.05 | — |
| ANIX | Anixa Biosciences Inc | $96.99M | $2.79 | — |
News headlines (Yahoo Finance, 1h cache)
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
2026-09-23 11:03 · Yahoo
Biomea Fusion Announces Proposed Public Offering of Securities
2026-09-22 20:05 · Yahoo
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
2026-09-04 13:55 · Yahoo
Biomea Fusion to Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
2026-08-24 11:00 · Yahoo
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
2026-08-13 11:00 · Yahoo
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-05 20:05 · Yahoo
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
2026-06-05 23:32 · Yahoo
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
2026-06-03 12:00 · Yahoo
Biomea Fusion to Participate at Upcoming Investor Conferences
2026-05-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.